Kjell Någren

Author PubWeight™ 95.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006 3.12
2 Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010 2.32
3 Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 2008 2.24
4 Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008 2.19
5 EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010 2.09
6 Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008 2.04
7 Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008 1.82
8 Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 2010 1.61
9 Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005 1.58
10 The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 2008 1.55
11 EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 2009 1.49
12 Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse 2007 1.46
13 EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging 2009 1.45
14 Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008 1.31
15 Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003 1.29
16 Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol 2007 1.27
17 A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012 1.21
18 Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005 1.14
19 Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology 2010 1.13
20 Altered dopamine D2 receptor binding in atypical facial pain. Pain 2003 1.10
21 Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010 1.10
22 C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 2009 1.10
23 Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002 1.07
24 Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord 2004 1.03
25 Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 2008 1.02
26 Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002 1.01
27 Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab 2006 1.00
28 C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuropsychopharmacol Biol Psychiatry 2009 1.00
29 Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis 2008 0.98
30 Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006 0.98
31 Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 2005 0.97
32 Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging 2012 0.96
33 Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects. Neuroimage 2008 0.96
34 Age-related loss of extrastriatal dopamine D(2) -like receptors in women. J Neurochem 2002 0.96
35 The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am J Physiol Endocrinol Metab 2008 0.95
36 Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain. Eur J Neurosci 2004 0.94
37 Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 2004 0.94
38 Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 2002 0.93
39 Sevoflurane and propofol increase 11C-flumazenil binding to gamma-aminobutyric acidA receptors in humans. Anesth Analg 2004 0.92
40 Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 2002 0.92
41 Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging 2009 0.92
42 Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 2004 0.91
43 Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2008 0.90
44 Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging 2002 0.90
45 Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol 2010 0.89
46 Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci 2004 0.89
47 Brain serotonin 1A receptor binding in bulimia nervosa. Biol Psychiatry 2004 0.89
48 Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 2008 0.89
49 Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging 2008 0.88
50 Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther 2011 0.87
51 Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 2005 0.87
52 Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities. Am J Physiol Endocrinol Metab 2011 0.87
53 Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 2009 0.87
54 Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med 2010 0.87
55 Whole-body distribution and metabolism of [N-methyl-11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography. Eur J Nucl Med Mol Imaging 2008 0.87
56 Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. Synapse 2002 0.87
57 Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. Psychiatry Res 2007 0.86
58 Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab 2010 0.86
59 COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo. Mol Imaging Biol 2009 0.85
60 Subanesthetic ketamine does not affect 11C-flumazenil binding in humans. Anesth Analg 2005 0.85
61 Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men. J Physiol 2008 0.85
62 Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects. Pain 2004 0.84
63 [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010 0.84
64 Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. J Nucl Med 2002 0.84
65 Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia. Neurosci Lett 2004 0.84
66 Development of an automated modular system for the synthesis of [11C]acetate. Nucl Med Commun 2010 0.84
67 Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med 2010 0.84
68 Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005 0.84
69 [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nucl Med Biol 2006 0.83
70 Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 2006 0.83
71 Substantial thalamostriatal dopaminergic defect in Unverricht-Lundborg disease. Epilepsia 2007 0.83
72 EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging 2010 0.82
73 Pancreatic glucose uptake in vivo in men with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab 2008 0.81
74 Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol 2010 0.81
75 Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function. Synapse 2008 0.81
76 Correlation of human cold pressor pain responses with 5-HT(1A) receptor binding in the brain. Brain Res 2007 0.81
77 Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport. Eur J Nucl Med Mol Imaging 2006 0.81
78 Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET. Eur J Nucl Med Mol Imaging 2002 0.80
79 Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride. Int J Neuropsychopharmacol 2004 0.80
80 Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography. Neuroimage 2013 0.80
81 Human dosimetry of carbon-11 labeled N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide extrapolated from whole-body distribution kinetics and radiometabolism in rats. Mol Imaging Biol 2009 0.80
82 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. J Nucl Med 2008 0.80
83 Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. J Nucl Med 2004 0.79
84 Temperament trait Harm Avoidance associates with μ-opioid receptor availability in frontal cortex: a PET study using [(11)C]carfentanil. Neuroimage 2012 0.79
85 PET examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter. Nucl Med Biol 2002 0.78
86 Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009 0.78
87 Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010 0.78
88 Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter. Bioorg Med Chem Lett 2002 0.77
89 Striatal μ-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects. Neurosci Lett 2012 0.77
90 Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg 2008 0.77
91 The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study. Psychiatry Res 2009 0.76
92 Cortical dopamine D2/D3 receptors and verbal memory in man. Neuroimage 2010 0.76
93 Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate. EJNMMI Res 2013 0.75
94 Differential associations between brain 5-HT(1A) receptor binding and response to pain versus touch. J Neural Transm (Vienna) 2009 0.75
95 Brain Cholinergic Function and Response to Rivastigmine in Patients With Chronic Sequels of Traumatic Brain Injury: A PET Study. J Head Trauma Rehabil 2017 0.75
96 Radiolabeling and biodistribution of methyl 2-(methoxycarbonyl)-2-(methylamino) bicyclo[2.1.1] -hexane -5-carboxylate, a potential neuroprotective drug. Life Sci 2003 0.75
97 Cognitive decline and amyloid accumulation in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2012 0.75